SFBC International Provides Update on its Miami Facility
19 Gennaio 2006 - 6:16PM
Business Wire
SFBC International, Inc. (NASDAQ:SFCC), a provider of drug
development services to branded pharmaceutical, biotechnology,
generic drug and medical device companies, today announced that at
a hearing before the Miami-Dade County (the "County") Unsafe
Structures Board (the "Board") on January 18, 2006, the Board has
accepted the Agreed Recommendation submitted by SFBC and a Building
Department Official. The Board announced that it will issue a
formal written decision (the "Decision") with regard to SFBC's
Miami, Florida facility located on Biscayne Boulevard (the
"Facility"). As a result of the Decision, SFBC will continue to
operate this Facility and will make improvements to the Facility
following the issuance of the building permit. Prior to yesterday's
hearing, a building application plan was submitted to the County by
SFBC to permit structural improvements to the Facility. The
building application plan was prepared by SFBC's general
contractor, professional architects and engineers, and planning
expert. SFBC expects the Decision will be issued by January 25,
2006. Upon issuance of this Decision, SFBC will have 90 days to
obtain a building permit. During the 90-day period, SFBC expects
that the County will issue comments to the submitted plans and SFBC
will be required to make adjustments to the submitted plans based
upon these comments. Assuming the permit is issued, SFBC will have
180 days from issuance in which to complete all necessary
improvements to the Facility. The Company is pleased with the
outcome of this hearing and looks forward to working closely with
County officials. About SFBC International, Inc. SFBC
International, Inc. provides early and late stage clinical drug
development services to branded pharmaceutical, biotechnology,
generic drug and medical device companies around the world. SFBC
has more than 30 offices located in North America, Europe
(including Central and Eastern Europe), South America, Asia, and
Australia. In early clinical development services, SFBC specializes
primarily in the areas of Phase I and early Phase II clinical
trials and bioanalytical laboratory services, including early
clinical pharmacology. SFBC also provides late stage clinical
development services globally that focus on Phase II through IV
clinical trials. SFBC also offers a range of complementary
services, including data management and biostatistics, central
laboratory services, medical and scientific affairs, regulatory
affairs and submissions, and clinical IT solutions. Additional
information is available on SFBC's website at http://www.sfbci.com.
Forward-Looking Statements The statements made in this press
release relating to issuance of the building permits and completion
of the necessary renovations are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
(the "Act"). Additionally words such as "seek," "intend,"
"believe," "plan," "estimate," "expect," "anticipate" and other
similar expressions are forward-looking statements within the
meaning of the Act. Some or all of the results anticipated by these
forward-looking statements may not occur. Factors that could cause
or contribute to such differences include, but are not limited to,
the inherent uncertainty of how the County officials will react in
reviewing the application and plans submitted by SFBC and the
ability of outside contractors and professionals retained by SFBC
to make the necessary improvements in compliance with the permits
and all applicable laws.
Grafico Azioni Sfbc (NASDAQ:SFCC)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Sfbc (NASDAQ:SFCC)
Storico
Da Ott 2023 a Ott 2024
Notizie in Tempo Reale relative a Sfbc (MM) (NASDAQ): 0 articoli recenti
Più SFBC International, Inc. Articoli Notizie